Prognostic factors of advanced stage non-small-cell lung cancer

##plugins.themes.academic_pro.article.sidebar##

Published Sep 9, 2016
Download
pdf
Vol. 94 No. 5 (2016): Issue May 2016

##plugins.themes.academic_pro.article.main##

Jihen Ben Amar
Boutheina Ben Safta
Haifa Zaibi
Besma Dhahri
Mohamed Ali Baccar
Saloua Azzabi

Abstract

Abstract:
Background: Lung cancer is the main cause of death from cancer in the world. The 5-year survival is about 15%. Despite the progress of medicine the mortality rate decreased only marginally. This poor prognosis is due to late diagnosis.
Aim: To evaluate overall survival and prognostic factors in patients locally advanced or metastatic non small cell lung cancer (NSCLC).
Methods: Retrospective study including 180 patients with non-small cell lung cancer hospitalized in the department of Charles Nicolle Hospital of Tunis between January 2007 and December 2014.
Results: The mean age was 61.5 years with a male predominance (93.3%). The median overall survival was 6 months. The poor prognostic factors were the performans status (PS) and early delays of management (<30 days). The factors that improve survival were surgical treatment and delays of management more than 45 days.
 Conclusion: The prognostic factors in locally advanced and metastatic NSLC in our patient were: PS, management delay and treatment. These factors should be considered in management of patient with advanced stage NSCLC.

Keywords:

non-small-cell lung cancer, prognosis, survival

##plugins.themes.academic_pro.article.details##

References

  1. Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104:569-77.
  2. Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier A. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 2008;44:115-22.
  3. Statistiques sanitaires mondiales 2012. Bibliothèque OMS 2012.
  4. Ben Abdallah, M., Zehani, S., & Hizem Ben Ayoub, W. (2009). Registre des Cancers Nord-Tunisie. Ministre de la Sante Publique Institut Salah Azaiez Institut National de la Sante Publique, Tunis, Tunisia.
  5. Dautzenberg B, Choukroun G. Cancers bronchopulmonaires primitifs non à petites cellules et tumeurs à malignité réduite. Encycl Méd Chir ( Elsevier Masson, Paris), Pneumologie 1998 :1-16.
  6. Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier A et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007;43:149-60.
  7. De Carol P, Benfield J. Lung cancer in young persons. J Thorac Cardiovasc Surg 1982;83:372—6.
  8. Sugio K, Ishida T, Kaneko S, et al. Surgically resected lung cancer in young adults. Ann Thorac Surg 1992;53:127-31.
  9. Dujon C, Azarian R, Petitpretz P. Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV. Caractéristiques et facteurs pronostiques à partir d'une série rétrospective. Rev Mal Respir 2009;26:952-60.
  10. Chermiti Ben Abdallah F, Ben Ali G, Sadok Boudaya M, Milka M, Chtourou A, Taktak S et al. Traitement et pronostic du cancer bronchique non à petites cellules au stade avancé. Rev Mal Respir 2014;31:214-20.
  11. Moro D, Nagy-Mignotte H, Bolla M, Colonna M, Brichon PY, Brambilla C, Schaerer R, Vrousos C : Evaluation de la survie et des facteurs pronostiques de 2000 cancers broncho-pulmonaires enregistrés en 10 ans dans une unité multidisciplinaire de cancérologie. Bull Cancer 1997;84:155-61.
  12. Paesmans M : Les facteurs pronostiques. Rev Mal Respir 2008;25:3S99-106.
  13. Finkelstein DM, Ettinger DS, Ruckdeschel JC : Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702-9.
  14. Wataya H, Okamoto T, Maruyama R, et al. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer 2009;64:341-5.
  15. Grivaux M, Zureik M, Marsal L, et al. Five year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 2009;26:37-44.
  16. D'Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:116-9.
  17. Widikker G, Rochat T, Simonet M. Non small cell lung cancer and thoracic surgery: the role of the primary care physician. Rev Médicale Suisse 2008;4:2208-11. 18. Moro-Sibilot D, Pluquet E, Zalcman G, et al. Quel traitement pour un patient de PS 2/3 ayant un cancer bronchique non à petites cellules (CBNPC) de stade IV ? Rev Mal Respir 2007;24:120-4.
  18. Mornex F, Martin E, Belliére A, Milleron B, Van Houtte P, Chapet O. Cancer bronchique non à petites cellules localement évolué: place de la chimiothérapie exclusive. Cancer Radiother. 2002;6:117-24.
  19. Patel S, Sanborn R, Thomas CJ. Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease. Thorac Surg Clin 2008;18:393-401.
  20. Furuse K, Fukuoka M, Kawahara M. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
  21. Chargari C, Deutsch E, Le Péchoux C. États des lieux desassociations chimioradiothérapeutiques et place potentielledes thérapies ciblées dans les cancers non à petites cellules 2009;13:114-22.
  22. Christensen E, Harvald T, Jendresen M. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg 1997;12:880-4.
  23. Kashiwabara K, Koshi S, Itonaga K. Outcome in patients with lung cancer found retrospectively to have had evidence of disease on past lung cancer mass screening roentgenograms. Lung Cancer 2002;35:237-41.
  24. Yorio J, Xie Y, Yan J, Gerber D. Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol 2009;4:1322-30.
  25. Quarterman R, McMillan A, Ratcliffe M. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;125:108-13.
  26. Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer 2001;34:243-52.
  27. Aragoneses F, Moreno N, Leon P. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 2002;36:59-63.
  28. Salomaa E, Sällinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005;128:2282-8.
  29. Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zureik M : 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006;8: 1-8.